Medical device and MedTech insights, news, tips and more

Teva’s Digital Inhaler Now FDA Cleared

January 2, 2019

digital inhaler

Jerusalem-based Teva Pharmaceuticals’ sensor-packed, app-connected digital inhaler has recently received marketing approval from the US FDA, according to a release from the company. The device will first become available next year through a “small number” of healthcare system pilot partnerships, with a full national launch currently planned for 2020.

Teva’s ProAir Digihaler is indicated for the prevention and treatment of bronchospasm among patients aged four years or older with reversible obstructive airway diseases such as asthma or COPD, as well as for the prevention of exercise-induced bronchospasm (EIB) among this same group.

The prescription digital albuterol dispenser houses a built-in module that detects and measures each use, and sends the recorded information to a Bluetooth-connected mobile app. With this, patients can review their inhaler usage and share the data with their doctor.

Why it matters

According to 2016 data from the CDC, roughly 26.5 million adults and children living in the US have asthma, and approximately 1.7 million emergency department visits with asthma as the primary diagnosis occurred in 2015. Easily recording inhaler use with the device not only helps patients and providers monitor adherence, but correct any errors when dispensing treatment.

“One of the challenges physicians are faced with in caring for their asthma and COPD patients is knowing if their patients are using their inhaled medication as they should. That’s what makes a product like this so important to doctor-patient discussions,” Dr. Tushar Shah, SVP of global specialty clinical development at Teva Pharmaceuticals, said in a statement. “Offering a tool that enables doctors to see data on their patients’ inhaler usage will allow them to have more productive conversations about identifying issues and how to manage their illness.”

What’s the trend

This month’s approval comes a bit over three years after Teva announced its purchase of Gecko Health Innovations, a Cambridge, Massachusetts-based maker of smart inhalers. At the time, Gecko’s leading product was CareTRx, a platform for chronic respiratory disease management that combined a connected sensor device, a data analytics platform, an accessible user interface and behavioral triggers to help asthma and COPD patients manage their condition.

Read More at the Source: Teva’s digital inhaler cleared by FDA | MobiHealthNews

Written by: Dave Muoio

A Speciality Recruiting Firm Exclusively Servicing The Medical Device Industry

Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.



More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.